CH639852A5 - Medicament contre les maladies infectieuses des voies urinaires et digestives. - Google Patents
Medicament contre les maladies infectieuses des voies urinaires et digestives. Download PDFInfo
- Publication number
- CH639852A5 CH639852A5 CH692479A CH692479A CH639852A5 CH 639852 A5 CH639852 A5 CH 639852A5 CH 692479 A CH692479 A CH 692479A CH 692479 A CH692479 A CH 692479A CH 639852 A5 CH639852 A5 CH 639852A5
- Authority
- CH
- Switzerland
- Prior art keywords
- sodium
- urinary
- strains
- lysates
- per liter
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title claims description 3
- 230000002485 urinary effect Effects 0.000 title claims description 3
- 230000001079 digestive effect Effects 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 239000006166 lysate Substances 0.000 claims description 23
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 4
- 208000035404 Autolysis Diseases 0.000 claims description 3
- 206010057248 Cell death Diseases 0.000 claims description 3
- 230000028043 self proteolysis Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 238000009630 liquid culture Methods 0.000 claims 2
- 235000013372 meat Nutrition 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 239000004251 Ammonium lactate Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 229940059265 ammonium lactate Drugs 0.000 claims 1
- 235000019286 ammonium lactate Nutrition 0.000 claims 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims 1
- 229940041514 candida albicans extract Drugs 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001540 sodium lactate Substances 0.000 claims 1
- 229940005581 sodium lactate Drugs 0.000 claims 1
- 235000011088 sodium lactate Nutrition 0.000 claims 1
- 235000019157 thiamine Nutrition 0.000 claims 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
- 239000011721 thiamine Substances 0.000 claims 1
- 239000012138 yeast extract Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH692479A CH639852A5 (fr) | 1979-07-26 | 1979-07-26 | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
| DE19803019448 DE3019448A1 (de) | 1979-07-26 | 1980-05-21 | Immunobiotherapeutisches arzneipraeparat und verfahren zu seiner herstellung |
| ES491920A ES8104402A1 (es) | 1979-07-26 | 1980-05-28 | Procedimiento para la preparacion de medicamentos inmunobio-terapicos a partir de cepas microbiologicas. |
| FR8012677A FR2462164A1 (fr) | 1979-07-26 | 1980-06-06 | Medicament contre les maladies infectieuses des voies urina ires et digestives a base d'un lysat bacterien provenant d'au moins une souche d'escherichia coli |
| HU801726A HU181725B (en) | 1979-07-26 | 1980-07-10 | Process for producing immunotherapeutic pharmaceutical composition |
| DD222593A DD153192A5 (de) | 1979-07-26 | 1980-07-14 | Verfahren zur herstellung eines immunobiotherapeutischen arzneipraeparates |
| RO80101780A RO80054A (ro) | 1979-07-26 | 1980-07-22 | Procedeu de obtinere a unui medicament destinat afectiunilor infectioase ale cailor urinare si digestive |
| IT49314/80A IT1143025B (it) | 1979-07-26 | 1980-07-24 | Medicamento contro le malattie infettive delle vie urinarie e digestive e procedimento per produrlo |
| BE0/201514A BE884456A (fr) | 1979-07-26 | 1980-07-24 | Medicament contre les maladies infectieuses des voies urinaires et digestives |
| PL1980225853A PL127520B1 (en) | 1979-07-26 | 1980-07-24 | Process for preparing medicine against infectious diseases of urinary and gastro-intestinal tracts |
| CS805266A CS212234B2 (en) | 1979-07-26 | 1980-07-25 | Method of making the immunotherapeutical means against the infection decease uf urine and digesting ways |
| YU1896/80A YU42532B (en) | 1979-07-26 | 1980-07-25 | Process for obtaining bacteria lizate from cultures of escherichia coli |
| PT71612A PT71612A (fr) | 1979-07-26 | 1980-07-25 | Procede de preparation d'un medicament contre les maladiesinfectieuses des voies urinaires et digestives |
| AR281940A AR222887A1 (es) | 1979-07-26 | 1980-07-25 | Procedimiento de preparacion de un medicamento inmunobioterapico y medio de cultivo para ponerlo en practica |
| JP10231580A JPS5622733A (en) | 1979-07-26 | 1980-07-25 | Immunity creature therapeutic drug and its manufacture |
| GB8024420A GB2054374B (en) | 1979-07-26 | 1980-07-25 | Bacterial lysates |
| HRP-1896/80A HRP921282B1 (en) | 1979-07-26 | 1992-11-16 | Process for obtaining bacterial lisate from the sorts of escherichia coli |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH692479A CH639852A5 (fr) | 1979-07-26 | 1979-07-26 | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH639852A5 true CH639852A5 (fr) | 1983-12-15 |
Family
ID=4317195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH692479A CH639852A5 (fr) | 1979-07-26 | 1979-07-26 | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2550707B1 (fr) * | 1983-08-17 | 1986-02-28 | Lipha | Medicament immunomodulateur d'origine biologique et son procede de preparation |
| US4740585A (en) * | 1984-07-30 | 1988-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic vaccine against urinary infections |
| EP2345421A1 (en) | 2003-06-23 | 2011-07-20 | Biotech Tools S.A. | Epitope composition for sublingual or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
| KR101666548B1 (ko) * | 2007-03-05 | 2016-10-14 | 옴 파르마 에스아 | 소화계나 비뇨계 장애를 위한 박테리아 추출물 및 이를 이용한 치료방법 및 그 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1336015A (en) * | 1970-06-03 | 1973-11-07 | Unilever Ltd | Rearing pigs |
| BE789864A (fr) * | 1971-10-14 | 1973-04-09 | Unilever Nv | Elevage des veaux |
| US3911109A (en) * | 1971-10-14 | 1975-10-07 | Lever Brothers Ltd | Rearing calves |
| JPS5219927B2 (enrdf_load_stackoverflow) * | 1972-06-08 | 1977-05-31 | ||
| GB1462384A (en) * | 1973-04-12 | 1977-01-26 | Unilever Ltd | Rearing of lambs |
| GB1560934A (en) * | 1975-05-07 | 1980-02-13 | Unilever Ltd | Methods for the resistance of non-human mammals to gastro-intestinal disorders |
| US4141970A (en) * | 1975-05-07 | 1979-02-27 | Internationale Octrooimaatschappij "Octropa" B.V. | Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections |
| US4136167A (en) * | 1975-06-12 | 1979-01-23 | Internationale Octrooi Maatschappij "Octropa" B.V. | Process for reducing the incidence of neonatal diarrhoea in pigs |
| GB1581776A (en) * | 1976-08-18 | 1980-12-17 | Smith Kline Rit | Vaccines against oedema disease of piglets |
-
1979
- 1979-07-26 CH CH692479A patent/CH639852A5/fr not_active IP Right Cessation
-
1980
- 1980-05-21 DE DE19803019448 patent/DE3019448A1/de active Granted
- 1980-05-28 ES ES491920A patent/ES8104402A1/es not_active Expired
- 1980-06-06 FR FR8012677A patent/FR2462164A1/fr active Granted
- 1980-07-10 HU HU801726A patent/HU181725B/hu unknown
- 1980-07-14 DD DD222593A patent/DD153192A5/de not_active IP Right Cessation
- 1980-07-22 RO RO80101780A patent/RO80054A/ro unknown
- 1980-07-24 BE BE0/201514A patent/BE884456A/fr not_active IP Right Cessation
- 1980-07-24 IT IT49314/80A patent/IT1143025B/it active
- 1980-07-24 PL PL1980225853A patent/PL127520B1/pl unknown
- 1980-07-25 JP JP10231580A patent/JPS5622733A/ja active Granted
- 1980-07-25 CS CS805266A patent/CS212234B2/cs unknown
- 1980-07-25 AR AR281940A patent/AR222887A1/es active
- 1980-07-25 GB GB8024420A patent/GB2054374B/en not_active Expired
- 1980-07-25 PT PT71612A patent/PT71612A/pt unknown
- 1980-07-25 YU YU1896/80A patent/YU42532B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL225853A1 (enrdf_load_stackoverflow) | 1981-05-08 |
| FR2462164B1 (enrdf_load_stackoverflow) | 1983-08-05 |
| GB2054374A (en) | 1981-02-18 |
| YU189680A (en) | 1983-06-30 |
| BE884456A (fr) | 1980-11-17 |
| FR2462164A1 (fr) | 1981-02-13 |
| JPS5622733A (en) | 1981-03-03 |
| PT71612A (fr) | 1980-08-01 |
| DD153192A5 (de) | 1981-12-30 |
| IT8049314A0 (it) | 1980-07-24 |
| ES491920A0 (es) | 1981-04-01 |
| YU42532B (en) | 1988-10-31 |
| DE3019448A1 (de) | 1981-02-12 |
| DE3019448C2 (enrdf_load_stackoverflow) | 1987-07-30 |
| CS212234B2 (en) | 1982-03-26 |
| GB2054374B (en) | 1983-06-22 |
| IT1143025B (it) | 1986-10-22 |
| AR222887A1 (es) | 1981-06-30 |
| RO80054A (ro) | 1982-10-26 |
| JPH0255407B2 (enrdf_load_stackoverflow) | 1990-11-27 |
| PL127520B1 (en) | 1983-11-30 |
| ES8104402A1 (es) | 1981-04-01 |
| HU181725B (en) | 1983-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4710379A (en) | Intestinal microflora-improving agent | |
| Gyaurgieva et al. | Meningitis caused by Rhodotorula rubra in an HIV-infected patient | |
| JP2000256202A (ja) | 新規な生体浄化活性型乳酸菌製剤 | |
| US4229440A (en) | Pharmaceutical composition containing the polysaccharide KGF-C as active ingredient | |
| JPS6320807B2 (enrdf_load_stackoverflow) | ||
| CH639852A5 (fr) | Medicament contre les maladies infectieuses des voies urinaires et digestives. | |
| TW200538047A (en) | A composition having immunoregulating activities | |
| Ferraz et al. | Rothia dentocariosa endocarditis and aortic root abscess | |
| CH620691A5 (enrdf_load_stackoverflow) | ||
| JP2969017B2 (ja) | 感染防御剤 | |
| CH680045A5 (enrdf_load_stackoverflow) | ||
| CH633188A5 (fr) | Medicament contre des maladies infectieuses des voies respiratoires. | |
| JPWO2005077390A1 (ja) | 血糖値低下剤、糖尿病治療・予防剤及びその製造方法 | |
| EP0139551B1 (fr) | Medicament immunomodulateur d'origine biologique et son procédé de préparation | |
| JPH08283166A (ja) | 感染防御剤 | |
| FR2481927A1 (fr) | Composition anti-allergique et son procede de preparation a partir d'une bacterie lactique du genre streptococcus | |
| JP7152733B2 (ja) | がん転移抑制剤 | |
| EP0600915B1 (fr) | Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine) | |
| EP0686039A1 (en) | Method of enhancing immune response to oral vaccines | |
| Jamieson et al. | Bacillary Dysentery in Dundee: A Comparative Study of Treatments | |
| JPH07238024A (ja) | 好中球機能改善剤 | |
| KR920005685B1 (ko) | 유산균을 이용한 항 종양제 | |
| JP2024102776A (ja) | 下痢・軟便の予防・軽減素材 | |
| FR2762785A1 (fr) | Lysat de bacteries cultivees du genre arthrobacter utile en tant qu'additif pour retablir et maintenir des taux de cholesterolemie physiologiquement acceptables, procede de preparation dudit produit et compositions le contenant | |
| JPH1171297A (ja) | 癌細胞アポトーシス誘導能増強剤及び癌細胞アポトーシス誘導性組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Supplementary protection certificate filed |
Free format text: OICM 46600/871014 |
|
| NV | New agent |
Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS |
|
| SPCG | Supplementary protection certificate granted |
Free format text: OICM 46600/871014, 960209, EXPIRES:20021014 |
|
| PL | Patent ceased |